{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-096633","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2023-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.255292+00:00","generated_at":"2026-06-07T10:37:47.111316+00:00","sec_items":["5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Positive interim Phase 2 data for TFF VORI and TFF TAC; company to accelerate to registration-enabling studies","bullets":["All five TFF VORI patients achieved clinical and mycologic responses; no all-cause mortality or discontinuations due to AEs.","All four TFF TAC patients transitioned from oral tacrolimus with reduced blood levels; no acute rejection; kidney function maintained.","Company plans to accelerate initiation of registration-enabling studies for both TFF VORI and TFF TAC.","1-for-25 reverse stock split effective December 19, reducing shares from ~59M to ~2.4M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-096633","json":"https://secwatch.observer/filing/0001213900-23-096633.json","markdown":"https://secwatch.observer/filing/0001213900-23-096633.md","text":"https://secwatch.observer/filing/0001213900-23-096633.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/0001213900-23-096633-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/ea190285-8k_tffpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T10:37:47.111316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d51f93ccd07ca21b2cfdc0f1579be7c02e0c5eec","claim":"TFF Pharmaceuticals, Inc.: Filed Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2023-12-19).","evidence_excerpt":"On December 18, 2023, TFF Pharmaceuticals, Inc. (the “Company”) filed with the Delaware Secretary of State a Certificate of Amendment (“Amendment”) to its Second Amended and Restated Certificate of Incorporation to effect a one for twenty-five (25) reverse stock split (“Reverse Split”) of its issued and outstanding shares of common stock. The effective time of the Reverse Split is 12:01 AM ET on December 19, 2023.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390023096633/0001213900-23-096633-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-12-19"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}